Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lucicebtide (Compound ST101) acts as a selective antagonist of CCAAT/enhancer-binding protein β (C/EBPβ). By binding to the leucine zipper domain of C/EBPβ, it inhibits its dimerization and facilitates its degradation via a ubiquitin-dependent pathway. Lucicebtide halts the cell cycle at the G0/G1 phase and demonstrates cytotoxic effects on cancer cells. Additionally, it shows favorable pharmacokinetic properties and effectively suppresses tumor growth in a mouse model [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Lucicebtide (Compound ST101) acts as a selective antagonist of CCAAT/enhancer-binding protein β (C/EBPβ). By binding to the leucine zipper domain of C/EBPβ, it inhibits its dimerization and facilitates its degradation via a ubiquitin-dependent pathway. Lucicebtide halts the cell cycle at the G0/G1 phase and demonstrates cytotoxic effects on cancer cells. Additionally, it shows favorable pharmacokinetic properties and effectively suppresses tumor growth in a mouse model [1]. |
Molecular Weight | 4724.46 |
Formula | C208H345N69O55S |
Cas No. | 2407100-74-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.